The Preliminary Results of Bortezomib Used as A Primary Treatment for An Early Acute Antibody-Mediated Rejection after Kidney Transplantation—A Single-Center Case Series

Proteasome inhibitor bortezomib has been used in the treatment of refractory cases of acute and chronic antibody-mediated rejection (AMR) in kidney transplant recipients. However, its efficacy and safety as a primary treatment for early AMR has been scarcely investigated. We herein present our preli...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolonko, Aureliusz, Słabiak-Błaż, Natalia, Karkoszka, Henryk, Więcek, Andrzej, Piecha, Grzegorz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074248/
https://www.ncbi.nlm.nih.gov/pubmed/32075220
http://dx.doi.org/10.3390/jcm9020529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074248/
https://www.ncbi.nlm.nih.gov/pubmed/32075220
http://dx.doi.org/10.3390/jcm9020529

Ejemplares similares